• US: +1 9176726599
  • Login

Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Status (2017-2021) and Forecast Market Analysis, Regional Outlook, Segment Growth Potential, and Competitive Market Share Analysis, 2022-2028

Format: PDF | Pages: 407 | Report ID: MRS1186


Report Description

The global Endoscopic Retrograde Cholangiopancreatography (ERCP) market was worth USD 1,407.8 million in 2021 and is expected to be worth USD 2,690.9 million by 2028, growing at a CAGR of 8.3% between 2022 and 2028.

Endoscopic retrograde cholangiopancreatography is a radiologic imaging procedure used to treat biliary diseases that combines endoscopy and fluoroscopy. This technique is mostly used to diagnose diseases involving the pancreatic ductal systems.

Market Trends

The worldwide endoscopic retrograde cholangiopancreatography market is being driven by rising incidences of chronic biliary disorders, growing demand for minimally invasive surgeries, coupled with an increase in the frequency of benign tumors of the liver and pancreas. Gastrointestinal (GI) illnesses affect several portions of the GI tract as well as digestive organs such as the liver, pancreas, and gallbladder. GI illnesses affect millions of individuals and are a major cause of morbidity and mortality worldwide. For example, according to the International Foundation for Gastrointestinal Disorders Report issued in 2020, GERD affects around one-third of the overall population, causing bleeding difficulties which are fueling the global market's growth. GI illnesses affect 60–70 million Americans each year, with the National Institutes of Health allocating up to USD 1.6 billion to GI research in 2017. In contrast, the incidence of primary biliary cholangitis (PBC) is 5-15 cases per million people. A significant increase in mortality rates has grabbed the attention of governments, and hence the need for treatment is projected to rise in the predicted period.

Pancreatic cancer is the ninth most prevalent cancer in women and the tenth most common cancer in males, according to the American Cancer Society. It is the fourth-largest cause of death from cancer in both men and women. It is responsible for 7% of all cancer fatalities. The vast majority of pancreatic malignancies (93%) are exocrine adenocarcinomas, with only 7% being pancreatic neuroendocrine tumors. As a result, individuals are more aware of the danger, and they seek better care. As a result, prominent medical organizations are likely to increase their investments in endoscopic retrograde cholangiopancreatography, which is expected to fuel market growth throughout the forecast period.

Segmentation Insights

On the basis of types, the industry is categorized into several categories, including Endoscopes, Endotherapy Devices, Spincterotome, Lithotripter, Stents, Cannulas, Balloons, Forceps, Catheters, Guiding Wires, Snares, and Baskets.

Endotherapy devices held the largest share in 2021 and are anticipated to maintain their dominance during the forecast period, owing to an increase in demand for ERCP therapeutic procedures and an increase in the prevalence of pancreatitis, choledocholithiasis, gallbladder stones, and other bile duct & pancreatic duct diseases. Furthermore, in terms of Endotherapy devices, the stents and sphincterotome sectors accounted for the biggest market in 2021 and are expected to increase at a CAGR of 3.7 percent and 3.8 percent, respectively, over the projected period.

The biliary sphincterotomy segment accounted for the biggest share in 2021, accounting for more than two-fifths of the worldwide endoscopic retrograde cholangiopancreatography industry, and is anticipated to continue its lead position during the forecast period. The pancreatic sphincterotomy category, on the other hand, is predicted to grow at the fastest rate of 7.6 percent between 2022 and 2028.

The endoscopic Retrograde Cholangiopancreatography Market based on end-user can be further segmented into Hospitals and Clinics, Ambulatory Surgical Centers, Laboratories, and Others. In 2021, the Hospitals and Clinics sector held the greatest market share. This expansion is due to the rapid development of healthcare infrastructure in the North American and European regions, which has aided in the financial development of hospitals. Patients' increasing need for treatment in hospitals including devices such as sphincterotomes, as well as improved preventative care and enhanced treatment alternatives in clinics, is boosting the expansion of this category even further.

Competitive Insights

The global endoscopic retrograde cholangiopancreatography market is extremely competitive, with both local and global players present. The key players are pursuing various growth strategies, such as product launches, acquisitions, and partnerships, which are contributing to the market's global expansion.

For instance, In January 2022, Cook Medical (US) introduced the Instinct Plus endoscopic clipping device which is compatible with a duodenoscope and offers applications for defect closure, anchoring treatments, and preventative clipping in the gastrointestinal (GI) tract.

Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):

  • Olympus Corporation
  • Conmed Corporation
  • Hobbs Medical, Inc.
  • TeleMed Systems, Inc.
  • Boston Scientific Corporation
  • Cook Group incorporation
  • Fujifilm Holdings Corporation
  • Becton, Dickinson, and Company
  • Medtronic, Plc.
  • Ambu Inc.

Product Type Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Endoscopes
  • Endotherapy Devices
  • Spincterotome
  • Lithotripter
  • Stents
  • Cannulas
  • Forceps
  • Snares
  • Catheters
  • Guiding Wires
  • Balloons
  • Baskets
  • Others

Application Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Biliary Sphincterotomy
  • Biliary Dilatation
  • Biliary Stenting
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Dilatation
  • Pancreatic Duct Stenting

End User Coverage (Market Size & Forecast, Main Consumer Analysis, etc.):

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Laboratories
  • Others

Region Coverage (Regional Consumption, Demand & Forecast by Countries, etc.):

  • North America (U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, etc.)
  • Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
  • South America (Brazil, Mexico, Argentina, etc.)
  • Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa, etc.)

Frequently Asked Questions

The global Endoscopic Retrograde Cholangiopancreatography (ERCP) market was worth USD 1,407.8 million in 2021 and is expected to be worth USD 2,690.9 million by 2028, growing at a CAGR of 8.3% between 2022 and 2028.
North America captured the highest revenue in 2021 and is projected to continue its dominance during the study period.
The global Endoscopic Retrograde Cholangiopancreatography (ERCP) market is growing at a CAGR of 8.3% between 2022 and 2028.
Asia Pacific (especially China, and India) region is projected to grow at the fastest growth rate during the study period.
The global endoscopic retrograde cholangiopancreatography market is extremely competitive, with both local and global players present. The key players are pursuing various growth strategies, such as product launches, acquisitions, and partnerships, which are contributing to the market's global expansion.

Why Choose Market Research Strategy?

  Authenticated Data Sources

We utilize market analysis/information from verified authenticated data sources to scoop accurate research reports

  Express Delivery

We understand the urgency of our clients and their clients' in the competitive space thus, deliver the report in minimum turnaround

  Gain Instant Access

Without further ado, choose us and get instant access to reliable analysis to help you make the right business decisions.

  Our Pledge to You

We abide by the information security policy and adheres to keep your private and business information confidential and secure.

Copyright © 2022 Market Research Strategy, All rights reserved.